Pan Cancer T
pancancer-t.com
Actively hiring
Network Security
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$10.8M
1 round on record
Latest round
$10.8M
Venture round · Dec 2025 · 9 mo ago
Backers
1
InnovationQuarter
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 13, 2025
Raised a round Venture round $10.8M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2025 | $10.8M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
InnovationQuarter Similar startupsby what they do, their industry and backers
About us. Our Leadership team is composed of seasoned professionals with a strong expertise in the orphan diseases and gene therapy field.
Home About us Our Team Our Product Pipeline Our Supporters Science & Technology Publications Contact Us Our Team Lalit Pai Chief Executive…
0 About Us Ann Lee-Karlon, Ph.D. Chief Executive Officer and President Read more Shyra Gardai, Ph.D.
World-leading technical and scientific wireless innovations brought together in the heart of The Netherlands IoT semiconductor ecosystem.
Turn industrial reality into engineering intelligence. From scans, P&IDs, isometrics and legacy engineering documents to verified 3D…
Home About Login Our Founders Rafay Khan Chief Executive Officer Steve Milton Chief Product Officer Our Mission We're passionate about…
News
Laboratory Research Technician - Cell Culture & Immunology
Company: Pan Cancer T B.V.Location: Leiden, South Holland, NetherlandsHours: 36-40 per weekContract type: 18-month fixed-term contract (with potential extension)Sector: R&D, Cell Therapy, Oncology, Immunology About Pan Cancer T Pan Cancer T is a next gene
Read more
Report
Pan Cancer T: €10 Million Funding Raised To Launch In-Human Trial Of TCR-T Cell Therapy For Triple-Negative Breast Cancer
Pan Cancer T B.V., a Rotterdam-based biotech developing next-generation T cell therapies for solid tumours, has raised €10 million to move its lead program, PCT1:CO-STIM, into a first-in-human clinical trial for women with triple-negative breast cancer, t
Read more
Report
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer
Rotterdam, the Netherlands - 8 December 2025 - Pan Cancer T B.V., a biotech company pioneering next-generation T cell therapies for solid tumours, today announced a EUR 10 million financing to advance its lead program, PCT1:CO-STIM, into a first-in-human
Read more
Report
Pan Cancer T announces that Dr. Helen Tayton-Martin has joined its board as an independent director
3 July 2025 - Rotterdam, The Netherlands - Pan Cancer T is pleased to announce the appointment of Helen Tayton-Martin as independent director to its Supervisory Board. Dr. Tayton-Martin was most recently Chief Business & Strategy Officer of Adaptimmune pl
Read more
Report
Pan Cancer T's potential recognised at MEET2WIN with two awards
On 5th-7th May, Pan Cancer T's CEO, Rachel Abbott, attended the 10th edition of MEET2WIN, the European partnering convention dedicated to the fight against cancer. Organised by the French platform MATWIN (a 100% subsidiary of Unicancer), the event brought
Read more
Report
Extended Partnership with NecstGen
Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have a
Read more
Report
4.25 Million in Seed Extension Round
Rotterdam, July 11 2024 Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round. This round includes a new investor InnovationQua
Read more
Report
Pan Cancer T are EIT Health Catapult Finalists
On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich. This marks the culmination of the EIT Health Catapult program, a unique competition and training progr
Read more
Report
Awarded the Seal of Excellence from the European Commission
Amongst a record number of applicants, Pan Cancer T's EIC Accelerator proposal has been awarded the Seal of Excellence. The EIC Accelerator Seal of Excellence and the EIC Transition activities Seal of Excellence are quality labels awarded to project propo
Read more
Report
Selected as semi finalist of the EIT Health Catapult venture challenge
Pan Cancer T's CEO Rachel Abbott, will participate in the semi finals of the EIT Health Catapult! For more information about the venture challenge see https://eithealth.eu/programmes/catapult/%C2%A0 The post Selected as semi finalist of the EIT Health Cat
Read more
Report
Show more news
Financials
Total raised
$10.8M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $10.8M | Details |